fashion -WSS

fashion

author：comprehensive 2025-09-06 01:57:36 - browse：747

a person wearing blue dress conducts a finger prick test on another person in a home setting — coverage from STAT — Adobe

The last decade has seen billions of dollars flow into digital health companies that promise to improve outcomes for the 38 million Americans living with type 2 diabetes. Their products aren’t cheap, but in the long term, they pitch to health plans and employers that these digital tools will help cut health care costs by preventing serious complications like amputation and kidney failure.

A systematic review by the Peterson Health Technology Institute found, though, that digital tools used to manage diabetes with the help of finger-stick blood glucose readings don’t result in clinically meaningful improvements over standard care. As a result, they don’t reduce health care spending — they drive it up.

“Most of the solutions in this category do not deliver clinical benefits that justify their cost,” Caroline Pearson, executive director of the institute, told STAT. Despite finding that some populations may benefit, the report concludes that current evidence doesn’t support broader adoption for most products.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Congress must give Medicare recipients genetic counseling access

hotspot

explore

WSS

Eye stem cell transplant could help restore vision in injured people

UnitedHealth quietly bought dozens of outpatient centers

Ukraine taking heavy casualties 10 weeks into its counteroffensive

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Just how do doctors, lawmakers, and the public define abortion?

How to bring more disabled researchers into academia

hotspot

fashion

knowledge

Virginia high school admissions case could be legal follow

Amylyx ALS drug failure raises questions and concerns

Medicare details structure of new drug price negotiation program

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Supreme Court strikes down use of affirmative action

How to bring more disabled researchers into academia

State Dept. review finds Biden bears some blame for Afghanistan failures

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Peter Hotez and the public health issue of online harassment

Change Healthcare cyberattack prompts Medicare loan program

Wikipedia

An interview with Robert F. Kennedy Jr. on vaccines

With psoriasis trial ahead, Alumis raises $259 million

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Novo Nordisk obesity pill bests Wegovy in early trial

Hilary expected to bring catastrophic, life

Clinical trials must include more disabled people

hotspot

explore

knowledge

hotspot